FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Genetic Testing, Prevention
Study : Removing ovaries before age 50 may increase the risk of chronic conditions for some women
Most relevant for: Women under 50 years of age who have had or are considering removing their ovaries
Removal of ovaries and fallopian tubes prevents ovarian cancer, but it may come with other health risks. Experts recommend removal of ovaries and fallopian tubes in women at high risk for ovarian cancer due to inherited mutations in BRCA or other genes linked to ovarian cancer risk. For these high-risk women the benefit of ovarian cancer prevention outweighs the risk of long-term complications. Based on a recent study, some researchers feel that for women who are not at increased risk for cancer, the risk for some chronic conditions is too high to consider removal of both ovaries. (11/1/16)
Read MoreRelevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study
As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Racial disparities in BRCA testing: Why?
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: African American women who have been diagnosed with breast cancer
Black women receive BRCA testing less frequently than white women. Why is that? Researchers thought the reason might be that black and white women see different health care providers. However, new research suggests that disparities in physician recommendations for testing are the cause: black women with breast cancer were less likely to receive physician recommendations for BRCA testing than white women with breast cancer. There is a need to ensure equity in physician testing recommendations for black women. (7/21/16)
Read MoreRelevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : Early research on a drug to prevent breast cancer
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women with a BRCA1 mutation
Many researchers are interested in non-surgical options to reduce the higher-than-average risk of developing breast cancer in BRCA mutation carriers. This research study identified a type of drug, called a “RANK ligand inhibitor,” that may prevent breast cancer. Among mice that were genetically engineered to have no BRCA1 genes, those that were given the drug developed tumors less frequently than those that did not. While this is an exciting early study for BRCA mutation carriers, more work and human clinical trials need to be done before this can be used as a prevention therapy in humans. (7/12/16)
Update added 11/24/19: The RANK ligand inhibitor, denosumab is currently being studied as a possible breast and ovarian cancer preventive agent in human clinical trials.
Read MoreRelevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : Breast cancer risk model updated for average risk women with genetic, lifestyle and environmental information
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women at average risk for breast cancer
A number of factors are known to increase breast cancer risk, but some of these factors have not been included in models to predict breast cancer risk. This study looks at an updated model that includes some of these factors, such as genetics, smoking, and drinking. The goal of the model is to give women a more individualized breast cancer risk assessment. (6/29/16)
Read MoreRelevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : Is breast cancer risk increased in women who test negative for the BRCA mutation in their family?
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women from a family with a known BRCA mutation who tested negative for the mutation in the family
Some women who do not carry a BRCA mutation, but come from a BRCA-positive family, still develop breast cancer. This research examines whether these women are at higher risk for breast cancer, or whether their risk is similar to women in the general population. (4/19/16)
Read MoreArticle : New York Times report demonstrates need for genetic counseling, but doesn’t give the whole story
Most relevant for: People diagnosed with breast cancer
A New York Times report discussed how genetic testing could provide “grim data” without guidance for patients. While this is a valid concern, this report does not sufficiently emphasize certain important issues regarding genetic testing, particularly the need for genetic counseling by a health care provider with expertise in genetics before and after genetic testing. (4/5/16)
Read MoreStudy : BRCA testing in young women with breast cancer
Most relevant for: Young women diagnosed with breast cancer who have not yet had genetic testing
National guidelines recommend genetic testing for BRCA mutations in young women who are diagnosed with breast cancer. However, little is known about how women decide to get testing, or how they use genetic information to decide on treatment options. This study found that genetic testing is increasing among young breast cancer survivors, and it explores some of the factors that play into patients’ decision making about genetic testing. (3/22/16)
Read MoreStudy : Do women who eat a high fiber diet have a lower risk of breast cancer?
Most relevant for: Adolescent and young adult women
Some researchers believe that dietary fiber may decrease breast cancer risk by lowering estrogen levels in the blood. However, many previous studies have failed to find a link between fiber consumption and lower breast cancer risk. The current study suggests that consuming high dietary fiber during adolescence and young adulthood may lower breast cancer risk, but more work needs to be done to confirm this finding. In the meantime, everyone is encouraged to eat a variety of high fiber foods for the many well-documented health benefits. (03/08/16)
Read MoreRelevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : What are the genetics underlying 12 different cancer types?
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People diagnosed with cancer
As gene sequencing has become more affordable, researchers and health care providers are now looking for mutations in many genes beyond BRCA1, BRCA2 and others that are associated with known hereditary cancer syndromes. By sequencing thousands of genes rather than just one or two, researchers can better understand which inherited mutations affect cancer risk. In this study, researchers sequenced thousands of genes in patients with one of 12 cancers, including breast, and catalogued which gene mutations are most commonly found in each cancer. (03/01/16)
Read More